Anil Koul

Last updated

Anil Koul
AnilKoulNew.jpg
Born (1972-06-01) 1 June 1972 (age 52)
India
Alma materMax-Planck Institute for Biochemistry (MPI), Munich Germany & CSIR-IGIB Delhi and Delhi University, India
AwardsAmerican Chemical Society (ACS) - Heroes of Chemistry Award (2020); Sun Pharma Research Award (2017); Johnson Medal (2013); Swiss-TB prize (2005)
Scientific career
InstitutionsInstitute of Microbial Technology, Chandigarh 160036, India. LSHTM, London, UK.

Anil Koul (born 1 June 1972) is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH), [1] a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India.

Contents

Anil is currently a member of scientific advisory board of CSIR, a high powered committee for scientific management of CSIR organization, chaired by principal scientific adviser to the Prime Minister, Prof. Vijay Raghavan.

Anil has more than 18 years of pharmaceutical R&D expertise and currently is vice president and Head of Global Public Health discovery at Johnson & Johnson (J&J). He is member of Board of Directors of Janssen Pharmaceutica NV, the European subsidiary of J&J.

Additionally, Anil was recently appointed as Professor of Translational Discovery at London School of Hygiene and Tropical Medicine (LSHTM), where he will set up a laboratory of Translational drug discovery. [2]

Anil's major scientific career achievement is his key role in discovery and development of new tuberculosis drug Bedaquiline - the first drug to be approved in the last 45 years for treatment of drug-resistant tuberculosis.

Early life and education

Anil was born in Srinagar, Kashmir and completed his secondary school education in Srinagar till 1990 and further Bachelor's and master's degrees from Delhi University. Anil obtained his PhD at Delhi University and at Max-Planck Institute (MPI) of Biochemistry in Germany in 2001. His initial research focused on kinase and phosphatase in the laboratory of Axel Ullrich [3] at MPI and subsequently in Axxima Pharmaceuticals, a biotech company in Munich. In 2004, Anil joined the US multinational Johnson & Johnson, He worked as senior director and headed its respiratory infections discovery unit based in Europe and US. In late 2016, Anil moved to India to run the CSIR-IMTECH in Chandigarh. [4]

Scientific contributions

Anil's key achievement has been as one of the core scientist at J&J involved in discovery of multi drug-resistant tuberculosis drug called Bedaquiline. [5] Bedaquiline has been conditionally approved in US, Europe and several high TB burden countries like India, China and South Africa. In 2013, the World Health Organization (WHO) put Bedaquiline on list of its Essential Medicines. [6] Bedaquiline received a prestigious Prix Galien Award for most innovative Orphan Drug (UK) in 2016. [7] In 2019, India's Health Ministry made Bedaquiline available across more than 500 Drug-resistant TB centers in India [8] to help India's #EndTB program. [9] Till date, Bedaquiline has been approved for use in more than 60 countries and is part of national TB eradication plans across the world. [10] In 2020, US FDA approved New Pediatric formulation of Bedaquiline (>=5 years). [11]

Anil has extensive scientific contributions to drug discovery and translational research. Anil and his team have discovered more than 3 other drug candidates, two of which are into late stage human testing including one for serious respiratory viral infections (RSV). [12] Anil has several publications in leading journals like Nature and Science and more than 25 international patents to his credit.

As Director IMTECH he oversaw R&D and non R&D staff of more than 350 people and was responsible for scientific strategy, finance, general administration, business development, procurement, communication & public relations. At IMTECH, Anil played a pivotal role in establishing new research divisions like medicinal chemistry, and virology centers. [13] He established several industry-academia partnerships like Zydus Cadila and a high end skill development centre in partnership with MERCK. [14] In 2018, IMTECH's Bioinformatics Unit was among top institutions in world in number of biological databases. [15] Anil made policy changes including 'ease of doing science' and a new centralized admin block.

Anil has played key roles in several high level government committees like:

Key awards and honors

In 2020, American Chemical Society (ACS) awarded Anil along with two of his colleagues the 'Heroes of Chemistry Award' [16] [17] for the discovery of Bedaquiline. ACS is one of the biggest non-profit organization chartered by the US Congress. [18] In 2017, Anil was conferred with 'Sun Pharma Science Foundation Award' [19] [20] by India's Health Minister for his contribution to discovery of Bedaquiline. He was also awarded with the 'Swiss-TB Award' (2005) by the Swiss Foundation for Pneumology Research [21] and Johnson Medal (2013). He has featured in Voice of America's (VOI) radio news analysis [22] and India's electronic news channels (NDTV) 'Every Life Counts Program'. [23]

Key Advisory Boards Membership

  1. Scientific Advisory Board Member, CSIR. [24]
  2. Research Council Member of CSIR-Central Drug Research Institute, Lucknow. [25]
  3. Board of Directors, Technology Business Incubator, Kalinga Institute of Industrial Technology, Bhubaneswar. [26]
  4. Member of Board of Directors, Janssen Pharmaceuticals NV, Belgium.

Related Research Articles

<span class="mw-page-title-main">Tuberculosis</span> Infectious disease

Tuberculosis (TB), also known colloquially as the "white death", or historically as consumption, is a contagious disease usually caused by Mycobacterium tuberculosis (MTB) bacteria. Tuberculosis generally affects the lungs, but it can also affect other parts of the body. Most infections show no symptoms, in which case it is known as latent tuberculosis. Around 10% of latent infections progress to active disease that, if left untreated, kill about half of those affected. Typical symptoms of active TB are chronic cough with blood-containing mucus, fever, night sweats, and weight loss. Infection of other organs can cause a wide range of symptoms.

<span class="mw-page-title-main">Tibotec</span>

Tibotec was a pharmaceutical company with a focus on research and development of the treatment of infectious diseases such as HIV/AIDS and hepatitis C. The company was founded in 1994 and then acquired by Johnson & Johnson and merged into its Janssen Pharmaceuticals division in 2002. The company is part of Johnson & Johnson Innovation Medicine business segment.

<span class="mw-page-title-main">Janssen Pharmaceuticals</span> Belgian pharmaceutical company

Johnson & Johnson Innovative Medicine is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly-owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.

TB Alliance is a not-for-profit product development partnership (PDP) dedicated to the discovery and development of new, faster-acting and affordable tuberculosis (TB) medicines. Since its inception in 2000, TB Alliance has worked to grow the field of available treatments for TB and now manages the largest pipeline of new TB drugs in history. It was founded in Cape Town, South Africa, and has since expanded. It is headquartered in New York City and has a regional office in Pretoria.

<span class="mw-page-title-main">Multidrug-resistant tuberculosis</span> Medical condition

Multidrug-resistant tuberculosis (MDR-TB) is a form of tuberculosis (TB) infection caused by bacteria that are resistant to treatment with at least two of the most powerful first-line anti-TB medications (drugs): isoniazid and rifampicin. Some forms of TB are also resistant to second-line medications, and are called extensively drug-resistant TB (XDR-TB).

<span class="mw-page-title-main">Bedaquiline</span> Medication used to treat tuberculosis

Bedaquiline, sold under the brand name Sirturo, is a medication used for the treatment of active tuberculosis. Specifically, it is used to treat multi-drug-resistant tuberculosis along with other medications for tuberculosis. It is taken by mouth.

The Institute of Microbial Technology (IMTECH), based in Chandigarh, India, is one of the constituent establishments of the Council of Scientific & Industrial Research (CSIR). It was established in 1984.

Koen Andries is a Belgian Janssen Pharmaceutica scientist and professor at the University of Antwerp. In 2005 he and his team published a discovery about a new di-Aryl-Quinoline-based drug (R207910), now called bedaquiline, which promises a shorter and simpler treatment for drug resistant Tuberculosis (TB).

<span class="mw-page-title-main">Gajendra Pal Singh Raghava</span>

Gajendra Pal Singh Raghava is an Indian bio-informatician and head of computational biology at the Indraprastha Institute of Information Technology.

Samir Kumar Brahmachari is an Indian biophysicist and Former Director General of the Council of Scientific & Industrial Research (CSIR) and Former Secretary, Department of Scientific and Industrial Research (DSIR), Government of India. He is the Founder Director of Institute of Genomics and Integrative Biology (IGIB), New Delhi and the Chief Mentor of Open Source for Drug Discovery (OSDD) Project. He is the recipient of J.C Bose Fellowship Award, DST (2012). In addition, he is one of the featured researchers in the India Cancer Research Database developed by Institute of Bioinformatics (IOB), Bangalore with support from the Department of Biotechnology, Government of India.

<span class="mw-page-title-main">Garikapati Narahari Sastry</span> Indian chemist

Garikapati Narahari Sastry is an Indian Chemist and a Professor at the Department of Biotechnology at IIT-Hyderabad. He served as Director of CSIR- North East Institute of Science and Technology, Jorhat Jorhat, Assam from 19 February 2019 and served there till 10 January 2024. After taking charge as the Director, he has worked towards converting knowledge in the areas of computational modelling and Artificial intelligence from basic to translational research, by working closely with society and industry. Ultimately, revitalizing the strength of science and technology is essential in achieving the self-reliant and strong India. In the era of Industry 4.0 and 5.0, combining our traditional wisdom with modern science appear to be indispensable in the sectors such as Education, Health, Agriculture, Industrial and Societal development at large. Prior to joining as the Director, he headed the Molecular Modelling Division at the CSIR Indian Institute of Chemical Technology in Hyderabad, India. Sastry has made pioneering contributions in the areas of computational chemistry and computational biology.

<span class="mw-page-title-main">Tuberculosis in India</span> Health issue in India

Tuberculosis in India is a major health problem, causing about 220,000 deaths every year. In 2020, the Indian government made statements to eliminate tuberculosis from the country by 2025 through its National TB Elimination Program. Interventions in this program include major investment in health care, providing supplemental nutrition credit through the Nikshay Poshan Yojana, organizing a national epidemiological survey for tuberculosis, and organizing a national campaign to tie together the Indian government and private health infrastructure for the goal of eliminating the disease.

Delamanid is sold under the brand name Deltyba, is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.

Gyan Chandra Mishra is an Indian immunologist, cell biologist and the director of the National Centre for Cell Science, Pune, known for his researches towards the therapeutic control of diseases such as HIV, tuberculosis and malaria. He was honoured by the Government of India in 2003 with Padma Shri, the fourth highest Indian civilian award.

Open Source Drug Discovery (OSDD) is a Council of Scientific and Industrial Research, India (CSIR)-led Team India Consortium with global participation offering a collaborative drug discovery platform for neglected tropical diseases like leishmaniasis, which draw limited attention of research-based pharmaceutical enterprises. This program has a global community with over 7500 participants from 130 countries comprising researchers, academia, students, industries, educational institutions and so on. Anyone who is committed to the discovery of drugs for neglected diseases in an open source mode can participate in the program. OSDD functions by bringing together experts from diverse backgrounds to focus on discovering and developing affordable drugs for tropical infections.

<span class="mw-page-title-main">Keertan Dheda</span>

Keertan Dheda MBBCh (Wits), FCP(SA), FCCP, PhD (Lond), FRCP (Lond), born in 1969, is a Professor of Mycobacteriology and Global health at the London School of Hygiene and Tropical Medicine (LSHTM) with an extra-mural joint appointment at the University of Cape Town (UCT), where he is a Professor of Respiratory Medicine.

Nagasuma Chandra is an Indian structural biologist, biochemist and a professor at the department of biochemistry of the Indian Institute of Science. She is known for her studies on Mycobacterium tuberculosis. The Department of Biotechnology of the Government of India awarded her the National Bioscience Award for Career Development, one of the highest Indian science awards, for her contributions to biosciences in 2008.

Dibyendu Sarkar is an Indian biochemist, molecular microbiologist and a Chief Scientist at the Institute of Microbial Technology. He is known for his studies on Mycobacterium tuberculosis (Mtb), the bacterial pathogen causing the disease of tuberculosis. His studies have been documented by way of a number of articles and Google Scholar, an online repository of scientific articles has listed 23 of them. He has also delivered invited speeches which included the Second Annual Meeting on Infectious Diseases held at the Indian Institute of Science in September 2017. He is an elected member of Guha Research Conference and a recipient of the Raman Research Fellowship of the Council of Scientific and Industrial Research. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2011.

Ashwani Kumar is an Indian microbiologist and the senior principal scientist at the Institute of Microbial Technology (ImTech). He is known for his studies on Mycobacterium tuberculosis, the causative agent of tuberculosis. His laboratory focuses on understanding the reasons for drug tolerance observed in humans. His laboratory hypothesizes that tuberculosis is a biofilm infection, so its treatment needs the administration of multiple drugs for at least six months. The Department of Science and Technology has awarded him Swarnajayanti Fellowship for 2016–2017. Department of Biotechnology has awarded him the National Bioscience Prize (2017-18). He was also selected for DBT/Wellcome Trust India Alliance Senior Fellowship. He was elected as a Fellow of the National Academy of Sciences, India, in 2022. For his contributions in tuberculosis pathogenesis, he was awarded with Shanti Swarup Bhatnagar Prize for Science and Technology 2022. He is considered as one of India's Leading Scientist in the field of Tuberculosis and his lab is doing some of the best research in India.

Phumeza Tisile is a healthcare activist from South Africa who advocates for making tuberculosis medication inexpensive and widely available. Tisile survived extensively drug-resistant tuberculosis (XDR-TB), enduring three years and 8 months of treatment. Tisile's initial misdiagnoses led to months of incorrect treatment, which caused her to become deaf. As an activist, Tisile advocates for improved access to tuberculosis (TB) diagnosis and treatment, improved counseling for patients, research into better treatments, and elimination of TB stigma.

References

  1. ↑ Kanwar, Shimona (13 August 2016). "From Belgium to city for Imtech". The Times of India . Retrieved 14 June 2018.
  2. ↑ "LSHTM". LSHTM.
  3. ↑ Laboratory of Alex Ullrich (http://www.biochem.mpg.de/en/rd/ullrich Archived 7 June 2017 at the Wayback Machine )
  4. ↑ "J&J scientist helping fight tropical diseases in India". 7 June 2017.
  5. ↑ SIRTURO- MDR-TB Drug (https://www.sirturo.com/)
  6. ↑ WHO Conditional Approval SIRTUR https://www.jnj.com/media-center/press-releases/sirturo-bedaquiline-receives-conditional-approval-in-the-european-union-for-the-treatment-of-multi-drug-resistant-tuberculosis
  7. ↑ "Winners – Galien Foundation" . Retrieved 11 June 2019.
  8. ↑ Health, Ministry of (6 January 2019). "For Drug-Resistant TB (DR-TB) patients, a better and newer drug regimen Bedaquiline is now available across 428 district level DR-TB centres and 148 specialized DR-TB centres. #SwasthaBharat #TB #Tuberculosis #EndTBpic.twitter.com/GWAYSwkwq5". @mohfw_india. Retrieved 11 June 2019.
  9. ↑ "National Strategic Plan for Tuberculosis Elimination 2017–2025" (PDF). tbcindia.gov.in. March 2017. Retrieved 26 November 2020.
  10. ↑ "TBFacts".
  11. ↑ "Drugs History - Sirturo".
  12. ↑ "Clinical Trials". 24 June 2021.
  13. ↑ ""IMTECH's translational science agenda holds a big promise"". 13 June 2019.
  14. ↑ "CSIR to establish a High-End Skill Development Centre in Chandigarh". pib.nic.in. Retrieved 20 April 2019.
  15. ↑ "Statistics - Database Commons". bigd.big.ac.cn. Retrieved 20 April 2019.
  16. ↑ "ACS Heroes of Chemistry".
  17. ↑ "American Chemical Society - Janssen J&J - 2020 Heroes of Chemistry". YouTube . 3 November 2020.
  18. ↑ "ACS".
  19. ↑ The Tribune (http://epaper.tribuneindia.com/1188387/ChandigarhTribune/CT_29_April_2017#page/2/1)
  20. ↑ Sun Pharma Science Foundation award- (http://www.sunpharma.com/responsibility/csr/ranbaxy-science-foundation Archived 9 June 2017 at the Wayback Machine )
  21. ↑ "2005 SwissTB Award: Drs. Liem Nguyen, Anne Walburger, Giorgio Ferrari, Anil Koul". www.swisstb.org. Retrieved 16 December 2018.
  22. ↑ Voice of America’s radio news http://www.voanews.com/a/little-progress-made-against-tuberculosis---114800769/171357.html
  23. ↑ India’s NDTV every life counts program https://www.youtube.com/watch?v=hDW5-2S4VkM
  24. ↑ "CSIR" (PDF).
  25. ↑ "Research Council" (PDF). www.cdri.res.in. 16 January 2019. Archived from the original (PDF) on 16 December 2018. Retrieved 16 December 2018.
  26. ↑ "KIIT | Kalinga Institute of Industrial Technology Bhubaneswar". KIIT. Retrieved 16 December 2018.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.